Mark P. Bowes, PhD*
*Medical Writer, Portland, Oregon
Address correspondence to: Mark P. Bowes, PO Box 82043, Portland, OR 97282. Email: firstname.lastname@example.org
Disclosure statement: Dr Bowes reports having no financial or advisory relationships with corporate organizations related to this activity.
Ultrasound contrast agents approved for use in the United States consist of microbubbles of high-density, high-molecular-weight gasses (perflutren or sufur hexafluoride) encapsulated by protein, lipid, or polymer shells. These agents enhance the reflection of ultrasound waves, increasing the signal-to-noise ratio and improving visualization of the vasculature. Indications approved by the Food and Drug Administration (FDA) include echocardiography (perflutren protein-type a microspheres [Optison, GE Healthcare, Chicago, IL], perflutren lipid microspheres [Definity, Lantheus Medical Imaging, Inc, Billerica, MA], and sulfur hexafluoride lipid-type A microspheres [Lumason, Bracco Imaging, Monroe Twp, NJ]); as well as evaluation of liver masses in adults and pediatric patients, and vesicouretral reflux in pediatric patients (Lumason only). Clinical practice guidelines from the American Society of Echocardiography, the Intrasocietal Accreditation Commission, and many international organizations provide guidance for sonographers on indications and uses of contrast agents, developing institutional policies, and contrast safety. Ultrasound contrast agents have an excellent overall safety profile and a low risk of serious adverse events. FDA-mandated contraindications and warnings have evolved over the last decade as a number of large clinical studies have confirmed the effectiveness and safety of ultrasound contrast for a variety of applications. All approved ultrasound contrast agents carry a black-box warning regarding the risk of cardiopulmonary reactions, including fatalities, which have occurred uncommonly during or following administration. The risk of adverse reactions may be greater in patients with preexisting cardiopulmonary conditions. The most common adverse event associated with contrast is headache. Other potential safety and tolerability concerns include anaphylactic reactions, use in patients with cardiovascular shunts, back pain (especially in patients receiving Definity), and use in women who are pregnant or nursing. Contrast-enhanced ultrasound guidelines emphasize the importance of a multidisciplinary team approach in the successful implementation of injected contrast agents. Sonographers have a critical role in identifying the need for contrast during a particular ultrasound examination, as well as working with hospital administrators to develop policies for the safe and effective use of contrast agents in imaging.
* This sample course is for reference purposes only. It is not currently available for earning CE credits. To earn ARRT CE credits please subscribe to eRADIMAGING where you will see a complete listing of all active and eligible CE courses.
Enter your email address to receive our new course alerts.